A First-In-Human study of HS-10383, a Selective P2X3 Receptor Antagonist for the treatment of Refractory or Unexplained Chronic Cough, in Healthy Chinese Subjects

被引：0
|
作者：
Li, Qian [1 ,2 ]
Chen, Ke-Guang [1 ,2 ]
Zhang, Ye-Hui [1 ,2 ]
Zhou, Hai-Yan [1 ,2 ]
Ye, Pan-Pan [1 ,2 ]
Song, Lin-Lin [1 ,2 ]
Zhao, Fu-Rong [1 ,2 ]
Shi, Jin-Yi [1 ,2 ]
Wu, Qiong [3 ]
Yu, Xiang-Qing [3 ]
Pan, Chao [3 ]
Yuan, Dong [3 ]
Xu, Miao [3 ]
Xing, Aiping [3 ]
Yang, Xin-Mei [1 ,2 ]
Zhao, Wei [1 ,2 ,4 ]
机构：
[1] Shandong First Med Univ, Dept Clin Pharm, Affiliated Hosp 1, Jinan, Peoples R China
[2] Shandong Prov Qianfoshan Hosp, Shandong Engn & Technol Res Ctr Pediat Drug Dev, Shandong Med & Hlth Key Lab Clin Pharm, Jinan, Peoples R China
[3] Jiangsu Hansoh Pharmaceut Grp Co Ltd, Dept Clin Pharm, Lianyungang, Peoples R China
[4] Shandong Univ, Sch Pharmaceut Sci, Minist Educ,Dept Clin Pharm, Key Lab Chem Biol,Cheeloo Coll Med, Jinan, Peoples R China
来源：
RESPIROLOGY | 2023年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO13-6
引用
收藏
页码：60 / 61
页数：2
相关论文
共 50 条
  • [1] P2X3 receptor antagonist in chronic cough
    Turner, Richard D.
    Rajakulasingam, Raj K.
    Bhowmik, Angshu
    Bothamley, Graham H.
    LANCET, 2015, 386 (9990): : 244 - 244
  • [2] Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough
    Muccino, David
    Green, Stuart
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2019, 56 : 75 - 78
  • [3] Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough
    Niimi, Akio
    Saito, Junpei
    Kamei, Tadashi
    Shinkai, Masaharu
    Ishihara, Hiroyuki
    Machida, Mitsuaki
    Miyazaki, Sayaka
    EUROPEAN RESPIRATORY JOURNAL, 2022, 59 (06)
  • [4] TREATMENT OF REFRACTORY OR UNEXPLAINED CHRONIC COUGH WITH GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, OVER 52 WEEKS IN TWO PHASE III CLINICAL TRIALS
    Dicpinigaitis, Peter
    Birring, Surinder
    Morice, Alyn
    Smith, Jaclyn
    Mcgarvey, Lorcan
    Pavord, Ian
    Nguyen, Allison
    Schelfhout, Jonathan
    Tzontcheva, Anjela
    Li, Qing
    Muccino, David
    La Rosa, Carmen
    CHEST, 2021, 160 (04) : 2361A - 2362A
  • [5] BASELINE CHARACTERISTICS FROM A PHASE 3, RANDOMIZED CONTROLLED TRIAL (COUGH-2) OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, IN REFRACTORY OR UNEXPLAINED CHRONIC COUGH
    Muccino, D.
    Morice, A.
    Birring, A.
    Mcgarvey, L.
    Dicpinigaitis, P.
    Pavord, I.
    La Rosa, C.
    Urdaneta, E.
    Assaid, C.
    Smith, J.
    CHEST, 2020, 157 (06) : 4A - 4A
  • [6] The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial
    Friedrich, Christian
    Francke, Klaus
    Birring, Surinder S.
    van den Berg, Jan Willem K.
    Marsden, Paul A.
    McGarvey, Lorcan
    Turner, Alice M.
    Wielders, Pascal
    Gashaw, Isabella
    Klein, Stefan
    Morice, Alyn H.
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [7] The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial
    Christian Friedrich
    Klaus Francke
    Surinder S. Birring
    Jan Willem K. van den Berg
    Paul A. Marsden
    Lorcan McGarvey
    Alice M. Turner
    Pascal Wielders
    Isabella Gashaw
    Stefan Klein
    Alyn H. Morice
    Respiratory Research, 24
  • [8] First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
    Klein, Stefan
    Gashaw, Isabella
    Baumann, Sybille
    Chang, Xinying
    Hummel, Thomas
    Thuss, Uwe
    Friedrich, Christian
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (10) : 4552 - 4564
  • [9] Baseline characteristics from a phase 3, randomized controlled trial (COUGH-1) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
    Muccino, D.
    Morice, A.
    Birring, S. S.
    Mcgarvey, L.
    Dicpinigaitis, P., V
    Pavord, I. D.
    La Rosa, C.
    Urdaneta, E.
    Assaid, C.
    Smith, J. A.
    ALLERGY, 2020, 75 : 339 - 340
  • [10] Cough Triggers and Symptoms Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Trials of the P2X3 Receptor Antagonist Gefapixant (COUGH-1 and COUGH-2)
    Morice, Alyn
    Birring, Surinder
    Dicpinigaitis, Peter
    McGarvey, Lorcan
    Pavord, Ian
    Smith, Jaclyn
    La Rosa, Carmen
    Li, Qing
    Nguyen, Allison Martin
    Schelfhout, Jonathan
    Tzontcheva, Anjela
    Muccino, David
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB61 - AB61
12345